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Vasopeptidase inhibitors are a novel and effective strat-Vasopeptidase inhibition attenuates the progression of renal
egy for treating cardiovascular diseases, including hyper-injury in subtotal nephrectomized rats.
Background. Vasopeptidase inhibitors are a new class of car- tension and heart failure. By simultaneously inhibiting
diovascular compounds that inhibit both angiotensin-converting both angiotensin-converting enzyme (ACE) and neutral
enzyme (ACE) and neutral endopeptidase (NEP). The aim of
endopeptidase (NEP), vasopeptidase inhibitors are asso-the present study was to explore the effects of omapatrilat, a
ciated with reduction in angiotensin II formation and pre-vasopeptidase inhibitor, on renal function and pathology in
subtotally nephrectomized (STNx) rats. vention of atrial natriuretic peptide (ANP) degradation
Methods. STNx rats were randomized to four groups and [1]. The vasopeptidase inhibitors, via interrupting multiple
treated for 12 weeks: no treatment (N  14); omapatrilat at a
vasoactive hormone pathways, may offer advantages overlow dose of 10 mg/kg (L, N  12) and at a high dose of 40
currently available therapies such as renin-angiotensinmg/kg (H, N  10); or an ACE inhibitor, fosinopril, at a dose
of 10 mg/kg (N 12). Sham-operated rats were used as control system (RAS) blockade with an ACE inhibitor, in terms
animals (N  12). of greater blood pressure reduction and cardiovascular
Results. Elevated blood pressure in STNx rats (174  9
benefits, with this issue under intensive investigation [2].mm Hg) was reduced by omapatrilat in a dose-dependent man-
Although chronic administration of the ACE inhibi-ner (L, 121  3 mm Hg; H, 110  3 mm Hg) and by fosinopril
(149  5 mm Hg). Proteinuria in STNx rats (246  73 mg/day) tors is associated with attenuation of progressive renal
was reduced by treatment with fosinopril (88  21 mg/day) injury in subtotal nephrectomized (STNx) rats [3–7], pro-and was normalized by treatment with omapatrilat (L, 30  4
gression of renal injury is not arrested. Alternative ormg/day; H, 20 2 mg/day vs. control 25 1 mg/day). Decreased
glomerular filtration rates, elevated plasma urea and creatinine adjunctive approaches warrant investigation. In the STNx
and glomerulosclerosis, and tubulointerstitial fibrosis were model of renal injury, short-term treatment with an NEP
ameliorated by omapatrilat and fosinopril to a similar degree. inhibitor increased urinary ANP and modulated natri-Compared with fosinopril, omapatrilat treatment was associ-
uresis without improving blood pressure or protein ex-ated with increased plasma renin activity and decreased renal
ACE and NEP binding in a dose-dependent manner. cretion [8, 9]. However, CGS 30440, a dual ACE/NEP
Conclusion. These findings suggest that vasopeptidase inhi- vasopeptidase inhibitor, conferred greater reduction in
bition may provide a useful strategy for the treatment of pro- proteinuria than benazepril, an ACE inhibitor, despitegressive renal disease.
similar effects on blood pressure [10]. At both low dose
and high dose, CGP 30440 achieved a similar reduction in
blood pressure and proteinuria over a period of six weeks
[10]. Whether further lowering blood pressure with a
vasopeptidase inhibitor could further ameliorate pro-
teinuria in this model of progressive renal injury remains
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dase inhibitor, at both low dose and high dose, in re-
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METHODS Kidney histopathology
Assessment of glomerulosclerosis and tubulointersti-Experimental protocol
tial injury was performed as described previously [7, 15].Experimental procedures were in accordance with the
In brief, 30 glomeruli in each kidney were graded fromNational Health and Medical Research Council of Aus-
0 to 4 according to the severity of the glomerular sclero-tralia guidelines for animal experimentation. STNx (N 
sis: 0 normal; 1 slight glomerular damage, the mesan-48) or sham surgery (control, N  12) was performed
gial matrix and/or hyalinosis with focal adhesion, involv-in eight-week-old male Sprague-Dawley rats (body
ing 25% of the glomerulus; 2  sclerosis of 25 to 50%;weight of 220 to 310 g) as described previously [6, 7]. In
3 sclerosis of 50 to 75%; and 4  sclerosis of 75% ofbrief, the STNx was performed by right nephrectomy,
the glomerulus [7, 15]. Twenty fields of tubulointerstitialfollowed by infarction of approximately two thirds of the
area in the cortex were observed and graded as follows:left kidney with selective ligation of all but one extrarenal
0  normal; 1  the area of interstitial inflammation andbranch of the left renal artery. Anesthesia was achieved
fibrosis, tubular atrophy, and dilation, with cast formationby intraperitoneal injection of pentobarbitone sodium
involving 25% of the field; 2  lesion area between(60 mg/kg body weight; Boehringer Ingelheim, Artar-
25 and 50% of the field; and 3 lesions involving50%mon, NSW, Australia). Following subtotal nephrectomy,
of the field [7, 15]. Indices of glomerular damage or
the animals were randomly allocated to an untreated group
tubulointerestitial lesion were calculated by averaging
(STNx, N 14) or the treatment with either a vasopepti-
the grades assigned to all glomeruli, or tubular fields.
dase inhibitor or an ACE inhibitor for 12 weeks. The The data were expressed relative to the control group.
vasopeptidase inhibitor omapatrilat (Bristol-Myers Squibb
Pharmaceutical Research Institute, Princeton, NJ, USA) In vitro autoradiography for renal ACE and NEP
was administered by daily gavage at a low dose of 10 Angiotensin-converting enzyme and NEP binding in
mg/kg/day (omapatrilat low dose, N  12) or at a high the kidney (N  5 per group) were assessed using in
dose of 40 mg/kg/day (omapatrilat high dose, N  10). vitro quantitative autoradiography as previously de-
The ACE inhibitor fosinopril (Bristol-Myers Squibb scribed [16–18]. The rat kidneys (N 5, per group) were
Pharmaceutical Research Institute) was administered at obtained after the animals were anesthetized with an
a dose of 10 mg/kg/day by gavage (fosinopril, N  12). intravenous injection of pentobarbitone sodium (60 mg/
The rats had unrestricted access to water and standard kg). The kidneys were removed, bisected, and snap fro-
rat chow. Systolic blood pressure (SBP) was measured zen in liquid nitrogen-cooled isopentane and stored at
by indirect tail-cuff plethysmography in prewarmed un- 20C. Twenty-micron sections were cut on a cryostat
anesthetized animals as previously described [11], every at 20C and then dehydrated overnight under reduced
four weeks after surgery. At the end of the experiment, pressure at 4C.
animals were anesthetized by intraperitoneal injection The sections were preincubated for 15 minutes in 10
of pentobarbitone sodium (60 mg/kg body weight). A mmol/L sodium phosphate buffer (pH 7.4). For renal
midline incision of the abdomen was made, and the rem- ACE binding, sections were incubated in a fresh volume
nant kidney was removed and weighed. A portion of of the same buffer containing selective ligand for ACE,
kidney was fixed in 10% formalin and embedded with 125I-MK351A (a tyrosyl derivative of enalaprilic acid)
paraffin with standard procedure. Four-micron paraffin [19], at room temperature for two hours. For renal NEP
sections of kidney were used for histopathology. Another binding, sections were incubated with same buffer con-
portion of the kidney was frozen in liquid nitrogen and taining selective ligand for NEP, 125I-RB104, 2-[(3-iodo-
stored at80C for the in vitro autoradiographic studies. 4-hydroxy)-phenylmethyl]-4-N-[3-(hydroxyamino-3-oxo-
1-phenylmethyl)-propyl]amino-4-oxobutanoic acid, at
Assessment of renal function room temperature for two hours [20]. After incubation,
Glomerular filtration rate (GFR) was measured using the sections were washed four times for one minute each
the 99mTc-DTPA method at the conclusion of the experi- in ice-cold buffer and were air dried at room tempera-
ment [12]. Prior to sacrifice, animals were housed in ture. All slides, including a set of radioactivity standards,
metabolic cages for 24 hours for collection of urinary were exposed to Kodak BioMax x-ray film at room tem-
samples and measurement of urinary protein excretion perature for five days [9]. Following exposure, the films
using the Coomassie Brilliant Blue Method [13]. Plasma were processed and the optical densities quantitated by
urea and creatinine concentrations were measured by a microcomputer imaging device (MCID Imaging Sys-
autoanalyzer (Beckman Instruments, Palo Alto, CA, tem, St. Catherines, Ontario, Canada) connected to an
USA). Blood samples were collected from the tail vein IBM AT computer. The computer program using the
of conscious rats before the animals were sacrificed for radioactivity standards constructed a calibration curve
of optical density versus radioactivity density. Specificthe measurement of plasma renin activity (PRA) [14].
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Table 1. Body weight, kidney weight, and kidney to body weight ratio
PRA angio-
Body weight Mean SBP tensin 1 Kidney weight Kidney:body
Group N g mm Hg nmol/L/h g weight mg/g
Control 12 58911 1302 10.30.4 1.980.04 3.350.11
STNx 14 41131a 1749a 1.70.2a 2.090.39 4.510.77a
Fosinopril 12 41517a 1495b 7.11.6b 1.950.14 4.610.17
Omapatrilat
Low dose 12 41422a 1213bc 9.11.4b 1.770.11 4.300.17
High dose 9 41124a 1103abc 19.02.1abc 1.500.14b 3.680.29b
Abbreviations are: SBP, systolic blood pressure; PRA, plasma renin activity; STNx, subtotal nephrectomy.
a P  0.01 vs. control
b P  0.01 vs. STNx
c P  0.01 vs. fosinopril
binding densities were calculated as the difference be-
tween total and nonspecific binding densities.
Statistical analysis
Data were analyzed by analysis of variance (ANOVA)
using the Statview SE program (Brainpower, Calabasas,
CA, USA) on a Macintosh iMac Computer (Cupertino,
CA, USA). Comparisons of group means were per-
formed by Fisher’s least significant difference method.
Data are shown as mean SEM unless otherwise speci-
fied. PRA data were analyzed after logarithmic transfor-
mation. A P value of less than 0.05 was viewed as statisti-
cally significant.
RESULTS
Body weight and kidney weight
Fig. 1. Data for systolic blood pressure (SBP) are shown at weeks 4, 8,Subtotally nephrectomized rats, regardless of their and 12 in the control (), subtotally nephrectomized (STNx;), or STNx
treatment, gained similar weight over the period of ex- treated with omapatrilat low dose (), high dose (), or fosinopril ()
groups. Data are mean  SEM; *P  0.05; **P  0.01 vs STNx; †P periment, which was much less than that observed in
0.01 vs fosinopril; #P  0.012, Omapatrilat L vs H; ANOVA with
control animals (Table 1). Kidney weight and the ratio repeated measures.
of kidney:body weight were increased in untreated STNx
rats compared with control rats. Rats treated with the
vasopeptidase inhibitor omapatrilat tended to have a mean blood pressure by approximately 25 mm Hg, less
lower kidney weight and kidney:body weight ratio, but than that achieved with low-dose omapatrilat.
omapatrilat only at the high dose was associated with
Plasma renin activityreduced kidney weight and kidney:body weight ratio
Subtotally nephrectomized rats were associated with(Table 1).
reduced PRA when compared with control animals (Ta-
ble 1). The administration of omapatrilat was associatedSystolic blood pressure
with increased PRA in a dose-dependent manner, withSerial SBP values at weeks 4, 8, and 12 after surgery
the level in the lower dose being similar to and in theare shown in Figure 1, and the mean values of these
high dose being higher than that observed in sham ani-measurements are calculated (Table 1). SBP was elevated
mals (Table 1). PRA was increased by treatment with
in untreated STNx rats. The vasopeptidase inhibitor oma- fosinopril to similar levels as observed in sham rats or
patrilat ameliorated the rise in SBP in a dose-dependent STNx rats treated with the lower dose of omapatrilat
manner. Rats treated with low-dose omapatrilat had sim- (Table 1).
ilar blood pressure to that observed in control rats. Rats
Urinary protein excretiontreated with high-dose omapatrilat had lower blood pres-
sure than rats treated with omapatrilat at low dose or Urinary protein excretion was significantly increased
in STNx rats (median 258 mg/day, range 106 to 637 mg/the control group. The ACE inhibitor fosinopril reduced
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Table 2. Glomerular filtration rate (GFR), plasma urea, and creatinine concentrations
GFR Plasma urea Plasma creatinine Proteinuria
Group mL/min/kidney mmol/L lmol/L mg/day
Control 3.20.2 71 502 241
STNx 0.710.1a 222a 1067a 26273a
Fosinopril 1.10.1ab 161ab 845ab 8821ab
Omapatrilat
Low dose 1.10.1ab 181ab 832ab 304b
High dose 1.00.1ab 181ab 875ab 201bc
GFR is for two kidneys in sham rats and in subtotally nephrectomized (STNx) groups represents remnant kidney alone.
a P  0.01 vs. control
b P  0.01 vs. STNx
c P  0.01 vs. fosinopril
day) when compared with sham rats (median 23 mg/
day, range 17 to 25 mg/day; Table 2). Treatment with
omapatrilat was associated with reduction in proteinuria
in a dose-dependent manner (low-dose median 26 mg/
day, range 9 to 55 mg/day; high-dose median 18, range
7 to 34 mg/day), with the lower dose vasopeptidase inhib-
itor being associated with levels of proteinuria similar
to that seen in sham animals (Table 2). Proteinuria was
reduced in fosinopril-treated rats (median 71mg/day,
range 19 to 242 mg/day), but to a level that was still
higher than in control or STNx animals treated with
either dose of omapatrilat (Table 2).
GFR, plasma urea, and creatinine clearance
Subtotally nephrectomized rats had decreased GFR
and increased plasma urea and creatinine levels when
compared with control animals (Table 2). These parame-
ters were reduced to similar levels with all treatments
and were still higher than that observed in control ani-
mals (Table 2). There were no significant differences in
GRF among STNx rats treated with either omapatrilat
or fosinopril (Table 2).
Kidney histology
Subtotally nephrectomized rats developed glomerulo-
sclerosis (Fig. 2A) and tubulointerstitial fibrosis (Fig. 2B)
compared with control animals. Both omapatrilat and
fosinopril reduced glomerulosclerosis and tubulointersti-
tial fibrosis to a similar extent.
In vitro autoradiography for renal ACE and NEP
In kidneys of control rats, ACE (Fig. 3A) and NEP Fig. 2. Glomerulosclerosis indices (A) and tubular injury indices (B)
(Fig. 3D) binding was noted in the cortex and inner in rats of the control, subtotally nephrectomized (STNx), or STNx treated
with omapatrilat or fosinopril groups. *P  0.01 vs control; †P  0.01medulla. In STNx, renal NEP was reduced compared
vs STNx.
with control rats where renal ACE trended to elevation
compared with control, but did not reach significance
DISCUSSION(Table 3 and Fig. 3). Treatment with omapatrilat causes
a dose-dependent inhibition of renal NEP and ACE The present study demonstrates the beneficial effects of
binding. ACE binding was reduced by omapatrilat in a long-term administration of omapatrilat, in a dose-depen-
dose-dependent manner compared with untreated STNx dent manner, on reducing blood pressure and proteinuria
and retarding glomerulosclerosis and tubulointerstitialrats and to a greater extent than fosinopril (Table 3).
Cao et al: Vasopeptidase inhibition and progressive renal injury 719
Fig. 3. Representative macroscopic autoradio-
graphs of renal angiotensin-converting enzyme
(ACE) in control (A), subtotally nephrecto-
mized (STNx) (B) and omapatrilat high dose
(C ), and renal NEP in control (D), STNx (E ),
and omapatrilat high dose (F ) groups. Repro-
duction of this figure in color was made possi-
ble by a grant from Bristol-Myers Squibb,
Princeton, NJ, USA.
Table 3. Renal angiotensin-converting enzyme (ACE) and proteinuria are considered important targets for re-
and neutral endopeptidase (NEP) binding
tarding progression of renal injury.
ACE binding NEP binding In the present study using STNx rats, omapatrilat re-
Group % duced blood pressure in a dose-dependent manner, con-
sistent with its hypotensive effects in other hypertensiveControl 1005 1005
STNx 1105 894a models, including those with low, normal, and high renin
Fosinopril 824ab 784a models of hypertension [21, 22]. The hypotensive action
Omapatrilat
of vasopeptidase inhibition has now been observed inLow dose 589abc 803a
High dose 306abcd 626abcd clinical studies [23].
Data are expressed as the percentage of the binding compared to sham. Since omapatrilat reduced proteinuria in a dose-depen-
a P  0.05 vs. control, b P  0.01 vs. STNx, c P  0.01 vs. fosinopril dent manner in an association with reduction in bloodd P  0.01 vs. low-dose omapatrilat
pressure, its effect on proteinuria may be entirely pres-
sure related. Indeed, it has been demonstrated that with
similar blood pressure reduction, blockade of the RASfibrosis in progressive renal injury. In the present study,
with either an ACE inhibitor or an angiotensin type 1the beneficial effects of omapatrilat were associated with
(AT1) receptor antagonist conferred a similar degree ofa concomitant inhibition of renal ACE and NEP activity,
renoprotection [5]. This issue has been further exploredas assessed by quantitative autoradiography with specific
by using accurate radiotelemetric assessment of bloodligands for these vasoactive enzymes. These findings ex-
pressure in the subtotal nephrectomy model [24]. Thesetend the results of previous studies showing beneficial
studies also showed the pressure-dependent nature ofeffects of vasopeptidase inhibitor in ameliorating renal
the benefits conferred by RAS blockers [24], as has ainjury [10], and suggest that vasopeptidase inhibition
recent study by our group in which a combination of anmay be a therapeutic approach for retarding progression
of renal injury in which reducing both blood pressure ACE inhibitor and an AT1 receptor antagonist conferred
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a greater reduction in proteinuria and blood pressure ment of proteinuria and renal structural injury. Such a
possibility has been recently suggested from studies usingthan single agent therapy [7].
a neutralizing antibody to transforming growth factor-Treatment with the vasopeptidase inhibitor was asso-
[25]. This treatment in a model of diabetic nephropathyciated with preservation of renal function, as assessed
was associated with a reduction in renal fibrosis, yet noby improved GFR and lower plasma urea and creatinine
effects on albuminuria [25].concentrations compared with untreated STNx rats. The
Tissue ACE measurements have been used previouslyeffects of vasopeptidase inhibition on renal function were,
as a marker of the degree of inhibition of local ACEhowever, similar to that achieved with an ACE inhibitor.
activity in various organs including the kidney [26]. Re-Although administration of either a vasopeptidase inhib-
duced kidney ACE binding has been demonstrated afteritor or an ACE inhibitor had no influence on weight gain,
administration of various ACE inhibitors and was shownvasopeptidase inhibitor-treated rats had reduced kidney
to correlate with the hypotensive efficacy of the drugsweight and kidney to body weight ratio compared with
[27]. Compared with untreated rats, both fosinopril andthe ACE inhibitor-treated rats. The mechanisms under-
omapatrilat inhibited renal ACE binding with the degreelying these differences in kidney weight are uncertain.
of inhibition correlating with their hypotensive effects.Since vasopeptidase inhibitor or ACE inhibitor-treated
In the present study, an increase in PRA was seen withrats gained similar weight over the period of experiment,
both drugs, particularly with a high dose of omapatrilat.a lower kidney weight and a subsequent lower kidney/
These findings are consistent with a recent study showingbody weight ratio in vasopeptidase inhibitor-treated ani-
more potent effects of omapatrilat compared with fosi-mals may represent a specific antitrophic effect of this
nopril in inhibiting angiotensin I hydrolysis [28].agent, which warrants further examination.
Although kidney NEP activity was mildly decreasedVasopeptidase inhibitor therapy was associated with sim-
in untreated rats compared with control rats, omapatrilatilar amelioration of glomerulosclerosis and tubulointer-
also inhibited renal NEP activity in a dose-dependentstitial fibrosis, as obtained by the ACE inhibitor alone,
manner, suggesting that NEP inhibition, as an additionaleven though vasopeptidase inhibition conferred greater
factor, may have contributed to its efficacy as a hypoten-hypotensive effects. Furthermore, the effect of omapatrilat
sive agent and in conferring renoprotection. Comparedon renal pathology was not further enhanced at a higher
with the fosinopril, the vasopeptidase inhibitor omapatri-dose. These findings are consistent with previous obser-
lat was associated with greater inhibition on both renalvations, which showed a similar relationship between blood
ACE and NEP and increased PRA. These findings sug-pressure reduction conferred by the RAS blockers and
gest that the superiority in reducing blood pressure andamelioration of renal pathological injury in this model
proteinuria with vasopeptidase inhibition involves not[7]. Specifically, we observed in that study that greater
only NEP inhibition, but also ACE inhibition.hypotensive and antiproteinuric efficacy of combined
ACE inhibition and AT1 receptor blockade was not asso-
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renal morphological abnormalities that would require blood pressure; STNx, subtotally nephrectomized.
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